Phase I Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T).

Trial Profile

Phase I Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T).

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2015

At a glance

  • Drugs Erlotinib (Primary) ; Panobinostat (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2015 to 1 May 2015.
    • 10 Jun 2014 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top